Note: Ingredients listed on restricted chemical lists
EC/CAS
208-534-8/532-32-1
Name of the chemical
Benzoic acid and its sodium salt
Concentration
<1%
EC/CAS
200-143-0/52-51-7
Name of the chemical
Bronopol
Concentration
<0.05%
EC/CAS
611-341-5/55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
<0.01%
General Information
Version
25/08/2023
Revision date
2023-08-25
Product name
SyClean Coconut Shower Gel Wash
Icons in SDS
Company Information
company name
Sybron (UK) Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
sales@sybron.co.uk
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
According to Regulation (EC) No. 1272/2008 (CLP) Classified
2.1 Classification of the substance or mixture
Eye Irrit. 2; H319, Causes serious eye irritation
Signal word
Warning
Hazard statements
Causes serious eye irritation. (H319)
Precautionary statements
If medical advice is needed, have product container or label at hand. (P101) Keep out of reach of children. (P102)
Prevention
Wash hands thoroughly after handling. (P264) Wear eye protection. (P280)
Response
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. (P305+P351+P338) If eye irritation persists: Get medical advice/attention. (P337+P313)
Storage
-
Disposal
-
Hazardous Ingredients
Alcohols, C12-14, ethoxylated, sulfates, sodium salts bronopol (INN);2-bromo-2-nitropropane-1,3- diol reaction mass of 5-chloro-2-methyl-2H- isothiazol-3-one and 2-methyl-2H-isothiazol- 3-one (3:1)
Additional information
Not applicable.
2.3 Other hazards
Additional warnings This mixture/product does not contain any substances considered to meet the criteria classifying them as PBT and/or vPvB. This product does not contain any substances considered to be endocrine disruptors in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605.
